Dear Reader,

We continuously strive to improve the content and design of *Human Vaccines and Immunotherapeutics* in order to make the journal as useful and attractive as possible for our readers. Starting with our current issue, the content will be organized by topic rather than by paper type. Regular submissions of all types (commentary, research paper, review, etc.) on a particular subject will be grouped and presented in one unit. This new concept will provide readers with a better overview of the contents of each issue, and help them to easily identify groups of papers published in a field of interest. For authors, this new concept offers greater visibility for their paper in that it will be picked up more often and easily in the context of related papers.

In this issue, we draw your attention to five contributions related to the topic of **New Targets**: current clinical development using MVA-based vaccines (reviewed by Inchauspé, et al.), universal fungal vaccines (reviewed by Hamad), preclinical development of a dengue DNA vaccine candidate (Raviprakash, et al.) immunogenicity and immune modulatory effects of in-silico L. donovani candidate peptide vaccine (Elfaki, et al.), and production of EV71 vaccine candidates (commentary by Chong, et al.). Two papers in this issue deal with **HIV**: vaccination outcome in HIV-infected children (reviewed by Cagigi et al.) and the role of CD4+ T cells in HIV vaccine development (commentary by Van Braeckel, et al.). Three papers are related to **Immunotherapy**: a case report on CIMAvax EGF vaccine for NSCL carcinoma (Cheng, et al.), use of Broncho-vaxom for preventing infection in immunosuppressive patients (Zhang, et al.), as well as the influence of protein-bound polysaccharide PSK on maturation of dendritic cells (Tan, et al.). Two reviews on therapeutic applications and vaccine delivery (both by Bazan, et al.) using phage display are published in the section **Technologies**. Two papers in this issue cover the topic **Hepatitis**: marketing experience with China's hepatitis A vaccine Healive (reviewed by Wu, et al.), and evaluation of the revaccination effect on non- and low- responders to hepatitis B vaccine (Han, et al.). Different aspects of **Influenza** are discussed: persistence of influenza vaccine-induced antibody (Severson, et al.), immune responses to H1N1 vaccine in HIV-infected adults (Chotirosniramit, et al.), and acceptance of vaccination by pregnant women (Honarvar, et al.). Finally, three papers relate to **Licensed and related vaccine**s: evaluation of a BCG strain co-expressing two M tuberculosis antigens (Wang, et al.), HPV vaccination in Syria (Al Moustafa, et al.), and clinical evaluation of a Tdap-IPV vaccine (Laurichesse, et al.).

Furthemore, this issue features a **Special Focus on Meningococcal Vaccines and Disease**, consisting of two original research papers and two commentaries. Two studies look at safety and immunogenicity of a tetravalent meningococcal conjugate vaccine in children (Vesikari, et al.) and toddlers (Vesikari, et al.). Meningococcal disease and vaccination in India (Verma, et al.), and the epidemiology of *N. meningitidis* serogroup Y in Europe (Bröker, et al.) are discussed in two commentaries.

Also in this issue, we are pleased to present the US-based company ImmunoCellular Therapeutics (IMUC) in our monthly News, Policy and Profiles (NPP) section. The company develops multi-targeted cancer immunotherapies that aim to eliminate cancer stem cells in addition to normal bulk tumor cells. Dr John Yu, Interim CEO and President of IMUC, kindly agreed to answer our questions. If you would like to see your company/organization portrayed in *Human Vaccines and Immunotherapeutics* (*HV&I*), please contact the Acquisitions Editor Eva Riedmann (eva\@landesbioscience.com). The NP&P track is also an excellent platform to share your opinion on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. Suggestions for commentaries and opinion pieces are welcome. As always, the NPP track features a selection of the latest news related to vaccines and immunotherapeutics.

We realize that many scientists wish for free access to and distribution of published articles. Thus, *HV&I* offers a flexible open access (OA) model with highly competitive OA fees. The cost to make an original research paper OA is \$750. For all other types of papers, the OA fee is \$500.

We offer several popular website features to our readers: With our iPad application you can read the full issue of *HV&I* anywhere, just as you would the print issue. Subscribe to our RSS feed to see the latest published papers and "Like" us on facebook for daily updates.

We wish you a nice holiday break, and hope that you will continue to support and enjoy reading *HV&I* next year.

Sincerely,

Ronald Ellis PhD

Editor-in-Chief

Eva M. Riedmann PhD

Acquisitions Editor
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